625446-78-8

Basic information

• Product Name: 3-[2-(2,4-dimethoxyphenyl)ethyl]-1-cyclopentylpropan-1-one
• Synonyms: 3-[2-(2,4-dimethoxyphenyl)ethyl]-1-cyclopentylpropan-1-one
• CAS NO: 625446-78-8
• Molecular Weight: 266.768
• Mol File: 625446-78-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-[2-(2,4-dimethoxyphenyl)ethyl]-1-cyclopentylpropan-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[2-(2,4-dimethoxyphenyl)ethyl]-1-cyclopentylpropan-1-one(625446-78-8)
• EPA Substance Registry System: 3-[2-(2,4-dimethoxyphenyl)ethyl]-1-cyclopentylpropan-1-one(625446-78-8)

Safety Data

• Hazardous Substances Data: 625446-78-8(Hazardous Substances Data)

Upstream product

• 33240-34-5 cyclopentylmagnesium bromide 
• 1857-56-3 3-(3-chloro-4-methoxyphenyl)propionic acid 
• 50638-47-6 4-bromo-2-chloro-1-methoxybenzene 
• 87453-54-1 (+/-)-1-cyclopentylprop-2-en-1-ol 

Downstream Products

• 625446-77-7 2-Chloro-7-(3-chloro-4-methoxy-phenyl)-5-cyclopentyl-5-hydroxy-3-oxo-heptanoic acid methyl ester 
• 625446-79-9 3-chloro-6-[2-(3-chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-4-hydroxy-5,6-dihydro-pyran-2-one 
• 625445-71-8 6-[2-(3-chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4-dione 

Relevant articles and documents

Identification and structure-based optimization of novel dihydropyrones as potent HCV RNA polymerase inhibitors

A novel class of non-nucleoside HCV NS5B polymerase inhibitors has been identified from screening. A co-crystal structure revealed an allosteric binding site in the protein that required a unique conformational change to accommodate inhibitor binding. Her

INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME

The invention relates to compounds of the formula (I) and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula (I), and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula (I). The invention also relates to methods of preparing the compounds of formula (I).